Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Biomarkers and Personalized Therapies in Non-Hodgkin Lymphomas
share announcement

Biomarkers and Personalized Therapies in Non-Hodgkin Lymphomas

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Disease Biomarker".

Deadline for manuscript submissions: 5 June 2024 | Viewed by 1778

Special Issue Editors

Dr. Joanna Zawitkowska

E-Mail Website
Guest Editor
Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, Gębali 6, 20-093 Lublin, Poland
Interests: non-Hodgkin Lymphoma; acute myeloid leukemia; hematopoietic stem cell transplantation; pediatric hematology
Dr. Eryk Jacek Latoch

E-Mail Website
Guest Editor
Department of Pediatric Oncology and Hematology, Medical University of Bialystok, 15-274 Bialystok, Poland
Interests: pediatric hematology; acute lymphoblastic leukemia

Special Issue Information

Dear Colleagues,

Non-Hodgkin lymphomas (NHL) are a group of cancers that originate in the lymphatic system, and they are known for their heterogeneity and varying responses to treatment.

This Special Issue of the Journal of Personalized Medicine emphasizes the importance of biomarkers in identifying specific subtypes of NHL and tailoring treatment strategies accordingly. Biomarkers, such as genetic
mutations, gene expression profiles, and protein markers, have shown promising results in predicting patient response to different therapies and guiding treatment decisions. By identifying these molecular markers, patients with NHL can receive more targeted and individualized therapies, leading to improved effectiveness and minimized side effects.

This Special Issue aims to publish original and/or review articles covering the state-of-the-art and future perspectives of biomarkers and personalized therapies in non-Hodgkin lymphoma. By attracting submissions on this topic, the aim is to advance the field of NHL treatment, promoting the integration of biomarkers and personalized therapies into routine clinical practice and ultimately improving patient outcomes in NHL management.

Dr. Joanna Zawitkowska
Dr. Eryk Jacek Latoch
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Non-Hodgkin Lymphoma (NHL)
  • biomarker
  • targeted and individualized therapies
  • personalized therapies
  • genetic mutations
  • gene expression profiles
  • protein markers

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

33 pages, 1192 KiB  
Review
CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma
by Magdalena Ostojska, Emilia Nowak, Julia Twardowska, Monika Lejman and Joanna Zawitkowska
J. Pers. Med. 2023, 13(11), 1595; https://doi.org/10.3390/jpm13111595 - 10 Nov 2023
Viewed by 1531
Abstract
Non-Hodgkin lymphomas (NHL) are a group of cancers that originate in the lymphatic system, especially from progenitor or mature B-cells, T-cells, or natural killer (NK) cells. NHL is the most common hematological malignancy worldwide and also the fourth most frequent type of cancer [...] Read more.
Non-Hodgkin lymphomas (NHL) are a group of cancers that originate in the lymphatic system, especially from progenitor or mature B-cells, T-cells, or natural killer (NK) cells. NHL is the most common hematological malignancy worldwide and also the fourth most frequent type of cancer among pediatric patients. This cancer can occur in children of any age, but it is quite rare under the age of 5 years. In recent decades, available medicines and therapies have significantly improved the prognosis of patients with this cancer. However, some cases of NHL are treatment resistant. For this reason, immunotherapy, as a more targeted and personalized treatment strategy, is becoming increasingly important in the treatment of NHL in pediatric patients. The objective of the following review is to gather the latest available research results, conducted among pediatric and/or adult patients with NHL, regarding one immunotherapy method, i.e., chimeric antigen receptor (CAR) T cell therapy. We focus on assessing the effectiveness of CAR-T cell therapy, which mainly targets B cell markers, CD19, CD20, and CD22, their connections with one another, sequential treatment, or connections with co-stimulatory molecules. In addition, we also evaluate the safety, aftermath (especially neurotoxicities) and limitations of CAR-T cell therapy. Full article
(This article belongs to the Special Issue Biomarkers and Personalized Therapies in Non-Hodgkin Lymphomas)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop